Why is There Still no Human Vaccine Against Lyme Borreliosis?
Lyme disease, transmitted by ticks, is a complex illness that can be difficult to diagnose but easy to treat in most early cases, yet difficult in its latest stage. Every year, infections with Borrelia burgdorferi sensu lato spirochetes cause thousands of new cases of illness around the world, including people with a normal immunological reaction. Prevention in the form of vaccines is difficult due to e.g. very high variability of Borrelia antigen proteins, which precludes the construction of an effective vaccine. After the withdrawal of the OspA vaccine (LYMErix) in the USA, despite promising results, no vaccine protecting humans against all pathogenic species from the B. burgdorferi s.l. group is available. Recent data indicate that an effective vaccine may require a combination of several antigens or multiple epitopes based on vector-borne proteins and several outer membrane proteins of Borrelia. With the discontinuance of Lyme vaccines, personal protective behavior and the avoidance of exposure in high-risk areas remain necessary resources of prevention.
No Supplementary Data.
No Article Media
Document Type: Review Article
Publication date: 2015
More about this publication?
- Folia biologica is an international quarterly journal that publishes papers on the broad field of experimental zoology, nuclear and chromosome research, and also ultrastructural studies. All papers are subject to peer reviews. Indexed in: ISI Master Journal List, Current Contents, Polish Scientific Journals Contents. I.F. 0.667
- Editorial Board
- Information for Authors
- Ingenta Connect is not responsible for the content or availability of external websites